Company news

Ionis Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

October 23, 2026

Ionis ranked #1 on Science’s Top Employers list

October 22, 2026

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

October 20, 2026

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

October 16, 2026

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

September 23, 2026

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

September 22, 2026

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

September 4, 2026

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

September 3, 2026

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

August 20, 2026

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

July 29, 2026

Ionis reports second quarter 2026 financial results and highlights progress on key programs

July 29, 2026

Ionis to hold second quarter 2026 financial results webcast

July 15, 2026

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

July 13, 2026

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

July 13, 2026

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

July 9, 2026

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

July 6, 2026

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

June 25, 2026

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

June 8, 2026

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

June 4, 2026

Ionis to host 2026 virtual Annual Meeting of Stockholders

May 4, 2026

Ionis reports first quarter 2026 financial results and highlights progress on key programs

April 29, 2026

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

April 28, 2026

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

April 21, 2026

Ionis to hold first quarter 2026 financial results webcast

April 15, 2026

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

March 22, 2026

Ionis announces changes to Board of Directors

March 8, 2026

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

February 26, 2026

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

February 25, 2026

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

February 24, 2026

Ionis updates time for fourth quarter and full year 2025 financial results webcast

February 17, 2026

Ionis to hold fourth quarter and full year 2025 financial results webcast

February 11, 2026

DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)

January 20, 2026

Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts

January 11, 2026

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

January 7, 2026

Ionis to present at 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

December 1, 2025

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

November 30, 2025

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

November 13, 2025

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

November 12, 2025

Ionis to present at upcoming investor conferences

November 11, 2025

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

November 10, 2025

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

November 8, 2025

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

November 5, 2025

Ionis reports third quarter 2025 financial results and highlights progress on key programs

October 28, 2025

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

October 26, 2025

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

October 22, 2025

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

October 20, 2025

Ionis to hold third quarter 2025 financial results webcast

October 15, 2025

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

October 6, 2025

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

September 21, 2025

Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.